Exparel for Postoperative Pain Management: a Comprehensive Review.
Exparel
Non-opioid
Opioid-free
Pain management
Postoperative pain
Journal
Current pain and headache reports
ISSN: 1534-3081
Titre abrégé: Curr Pain Headache Rep
Pays: United States
ID NLM: 100970666
Informations de publication
Date de publication:
23 Oct 2020
23 Oct 2020
Historique:
accepted:
17
09
2020
entrez:
24
10
2020
pubmed:
25
10
2020
medline:
17
8
2021
Statut:
epublish
Résumé
Multimodal pain management is the most effective way to treat postsurgical pain. However, the use of opioids for acute pain management has unfortunately been a significant contributor to the current opioid epidemic. The use of opioids should be limited and only considered a "rescue" pain medication after other modalities of pain management have been utilized. It may be difficult to curtail the use of opioids in the treatment of chronic pain; however, in the postsurgical setting, there is compelling evidence that an opioid-centric analgesic approach is not necessary for good patient outcomes and healthcare cost benefits. Opioid-related adverse effects are the leading cause of preventable harm in the hospital setting. After the realization in recent years of the many harmful effects of opioids, alternative regimens including the use of multimodal analgesia have become a standard practice in acute pain management. Exparel, a long-lasting liposomal bupivacaine local anesthetic agent, has many significant benefits in the management of postoperative pain. Overall, the literature suggests that Exparel may be a significant component for postoperative multimodal pain control owing to its efficacy and long duration of action.
Identifiants
pubmed: 33098008
doi: 10.1007/s11916-020-00905-4
pii: 10.1007/s11916-020-00905-4
doi:
Substances chimiques
Anesthetics, Local
0
Delayed-Action Preparations
0
Liposomes
0
Bupivacaine
Y8335394RO
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM